1. Introduction {#sec1}
===============

Cardiac hypertrophy, including physiological hypertrophy and pathological hypertrophy, is one of the most important adaptive mechanisms for the heart in various situations of stress \[[@B1]\]. Pathological cardiac hypertrophy is always associated with decreased cardiac dysfunction and poor prognosis, which can ultimately lead to heart failure \[[@B2]\]. In contrast, physiological hypertrophy induced by pregnancy or chronic exercise training is favourable for cardiac function \[[@B2]\]. Various epidemiological and experimental studies revealed that exercise training contributes to physiological cardiac hypertrophy, and it can attenuate the pathological hypertrophy related to cardiovascular diseases, such as myocardial infarction, heart failure, and cardiomyopathy \[[@B3], [@B4]\].

The biological mechanism underlying the physiological cardiac hypertrophy induced by exercise is complex and still incompletely elucidated \[[@B3]\]. In recent years, an increasing number of studies have identified that the microRNA (miRNA, miR) networks regulated by exercise could contribute to physiological cardiac hypertrophy \[[@B5]\]. miRNAs are a type of small noncoding RNA (18--23 bp) that can cause translational repression or cleavage of mRNAs and posttranscriptional silencing. miRNAs are considered to be promising therapeutic targets for numerous cardiovascular diseases and have been shown to play a key role in physiological hypertrophy by regulating various cellular functions, including decreasing fibrosis and apoptosis and inducing cell growth and angiogenesis \[[@B6]\]. Different studies focused on physiological hypertrophy identified various miRNAs and their potential pathways due to different experimental conditions; however, the most likely mechanism is still unclear \[[@B7]--[@B14]\]. In this study, we collected the current published data concerning miRNAs associated with physiological hypertrophy and predicted the most likely biological pathways underlying exercise-induced physiological cardiac hypertrophy using bioinformatics tools.

2. Methods {#sec2}
==========

2.1. Data Extraction {#sec2.1}
--------------------

We searched the PubMed website using the keywords "microRNA," "exercise," and "hypertrophy" to identify all of the published microRNAs associated with exercise-induced cardiac hypertrophy that were eligible for further bioinformatics analysis. We collected all the appropriate published articles and extracted all the data needed for further analysis.

2.2. Bioinformatics Analysis {#sec2.2}
----------------------------

The software MirPath v.3 from the DIANA tools website was used to identify potential miRNA target genes and pathways in our study. TargetScan was used in this study to predict the potential target genes and demonstrate the possible relationships among the databases. Pathway analysis was performed to determine the involvement of coexpressed genes in different biological pathways according to the Kyoto Encyclopedia of Genes and Genomes (KEGG). Gene Ontology (GO) analysis was used to investigate the pathways associated with biological processes, cellular components, and specific molecular functions corresponding to the target genes of miRNAs identified by the software TargetScan. In this study, *P* values less than 0.05 (*P* \< 0.05) were considered to be statistically significant.

3. Results {#sec3}
==========

3.1. The Profiles of Identified miRNAs {#sec3.1}
--------------------------------------

As [Table 1](#tab1){ref-type="table"} shows, 8 studies were included in our study. Mouse models were used in 2 studies and rat models were used in another 6 studies to investigate the miRNAs regulated by various types of exercise \[[@B7]--[@B14]\]. Swimming, running, jumping, or wheel running were applied in the above studies. A total of 23 miRNAs were found to be associated with exercise-induced physiological cardiac hypertrophy. A total of 12 miRNAs were upregulated after exercise, while 14 miRNAs were downregulated, and 3 miRNAs showed different results in different reports.

3.2. KEGG and GO Pathway Analysis {#sec3.2}
---------------------------------

KEGG pathway analysis was used to identify all the potential pathways corresponding to miRNAs regulated by exercise. As shown in [Table 2](#tab2){ref-type="table"} and [Figure 1(a)](#fig1){ref-type="fig"}, the significant (*P* \< 0.05) pathways corresponding to downregulated miRNAs were as follows: Fatty acid elongation, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Other types of O-glycan biosynthesis, Thyroid hormone synthesis, Tyrosine metabolism, Mucin type O-glycan biosynthesis, Other glycan degradation, Glycosphingolipid biosynthesis-lacto and neolacto series, Tryptophan metabolism, Gap junction, Proteoglycans in cancer, and signalling pathways regulating pluripotency of stem cells. The significant pathways corresponding to upregulated microRNAs were as follows: ECM-receptor interaction, Fatty acid degradation, Fatty acid metabolism, Amoebiasis, Fatty acid elongation, Protein digestion and absorption, PI3 K-Akt signalling, Tyrosine metabolism, Other types of O-glycan biosynthesis, Glycosphingolipid biosynthesis-lacto and neolacto series, Valine, leucine and isoleucine degradation, and Focal adhesion ([Table 3](#tab3){ref-type="table"} and [Figure 2(a)](#fig2){ref-type="fig"}).

Gene Ontology (GO) analysis was used to investigate the pathways associated with biological processes, cellular components, and specific molecular functions corresponding to the target genes of miRNAs identified by the software TargetScan. The pathways corresponding to the target genes of downregulated miRNAs included cell, intracellular biological process, anatomical structure development, molecular function, cellular component, organelle, cell differentiation, embryo development, chromosome organization, anatomical structure formation involved in morphogenesis, ion binding, and cell morphogenesis ([Figure 1(b)](#fig1){ref-type="fig"}). Similarly, the following pathways corresponded to the upregulated miRNAs: cell, intracellular, anatomical structure development, biological process, cell differentiation, embryo development, ion binding, molecular function, proteinaceous extracellular matrix, organelle, basement membrane, anatomical structure formation involved in morphogenesis, collagen type IV trimer, extracellular matrix structural constituent, chromosome organization, and cell morphogenesis ([Figure 2(b)](#fig2){ref-type="fig"}).

4. Discussion {#sec4}
=============

Exercise is widely known as a safe and well-accepted nonpharmacological strategy to improve cardiac function and protect the heart from cardiovascular disorders \[[@B15]\]. It is quite important to find the potential molecular pathways underlying the physiological cardiac hypertrophy induced by exercise. In recent years, an increasing number of studies have focused on miRNAs, which can inhibit the transcription of target mRNAs and regulate various biological pathways \[[@B16]\]. Various studies reveal that miRNAs regulated by exercise are associated with physiological cardiac hypertrophy processes \[[@B7], [@B8]\]. However, due to the various animal models and the various types of exercise training, different miRNAs and potential biological pathways have been reported in different studies. In several studies, some miRNAs were even reported to be regulated in opposite directions, and thus it is hard to determine which miRNAs and pathways are associated most with exercise-induced hypertrophy \[[@B8], [@B9]\]. In this study, we collected all the miRNA data from all the published articles about exercise-induced cardiac hypertrophy and investigated the most likely biological pathways using bioinformatics analysis.

The analysis of downregulated miRNAs regulated by exercise revealed that Fatty acid elongation pathway and Arrhythmogenic right ventricular cardiomyopathy (ARVC) pathway could be associated with the hypertrophy process. In the Fatty acid elongation pathway, ELOVL family member 6 (Elovl6) is a microsomal enzyme, which has been shown to regulate the monounsaturated Fatty acids and elongation of C12--16 saturated Fatty acids \[[@B17]\]. Elovl6 is associated with brown adipose tissue (BAT) thermogenic capacity, which could protect against cardiomyocyte injury and suppress cardiac remodelling in catecholamine-induced cardiomyopathy \[[@B18]\]. Our findings first indicate that exercise could contribute to physiological hypertrophy via regulating the Elovl6-BAT pathway. Arrhythmogenic right ventricular cardiomyopathy (ARVC) is typically an autosomal dominant heart muscle disease, which is always accompanied by ventricular enlargement, heart dysfunction, and lethal arrhythmias \[[@B19]\]. ARVC is one of the most common primary reasons of sudden death in young people and athletes. Experimental and clinical studies indicated that exercise might induce ARVC \[[@B20]\]. In this study, we also elucidate the potential association between exercise and ARVC via miRNA regulation.

The analysis of upregulated miRNAs induced by exercise revealed that the ECM-receptor interaction pathway is the most valuable one. It was recently identified that in the mouse model of angiotensin II-induced cardiac remodelling, ECM-receptor interaction pathway may be involved in the process of cardiac remodelling \[[@B21], [@B22]\]. Here, we also indicate the relationship between this pathway and cardiac hypertrophy using bioinformatics analysis. This association needs to be more clearly elucidated in the future. We speculate that exercise can decrease fibrosis by targeting the ECM-receptor interaction pathway.

In conclusion, we predicted the most likely biological pathways associated with physiological cardiac hypertrophy induced by exercise in this study through extracting published miRNA data and performing analysis using bioinformatics methods, which may help us better understand the regulatory networks of exercise-induced physiological cardiac hypertrophy. However, more in-depth studies and clinical investigations are still needed in the future.
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###### 

The microRNAs regulated by exercise.

  MicroRNAs                                  Exercise training          Regulation   Reference
  ------------------------------------------ -------------------------- ------------ ---------------------
  MiR-133a (rno-miR-133a-3p)                 Running & swimming         Down         17468766 & 21447748
  MiR-1 (rno-miR-1-3p)                       Running & swimming         Down         17468766 & 21447748
  MiR-27a (rno-miR-27a-3p)                   Swimming                   Up           21709209
  MiR-27b (rno-miR-27b-3p)                   Swimming                   Up           21709209
  MiR-143 (rno-miR-143-3p, mmu-miR-143-3p)   Swimming & wheel running   Down         21709209 & 24751578
  miR-26b (mmu-miR-26b-5p)                   Wheel running              Down         24751578
  miR-150 (mmu-miR-150-5p)                   Wheel running              Up           24751578
  miRNA-133b (rno-miR-133b-3p)               Swimming                   Down         21447748
  miRNA-29c (rno-miR-29c-3p)                 Swimming                   Up           21447748
  miRNA-214 (rno-miR-214-3p)                 Jumping                    Down         25822872
  miR-208b (rno-mir-208b)                    Swimming                   Up           25793527
  miR-30e (rno-miR-30e-5p)                   Swimming                   Up           25793527
  miR-19b (rno-miR-19b-3p)                   Swimming                   Up           25793527
  miR-99b (rno-miR-99b-5p)                   Swimming                   Down         25793527
  miR-100 (rno-miR-100-5p)                   Swimming                   Down         25793527
  miR-191a (rno-mir-191a)                    Swimming                   Down         25793527
  miR-22 (rno-miR-22-3p)                     Swimming                   Down         25793527
  miR-181a (rno-miR-181a-5p)                 Swimming                   Down         25793527
  miR-222 (mmu-miR-222-3p)                   Swimming & wheel running   Up           25863248
  miRNA-21 (rno-miR-21-5p)                   Swimming                   Up           23812090
  miRNA-145 (rno-miR-145-5p)                 Swimming                   Up           23812090
  miRNA-144 (rno-miR-144-3p)                 Swimming                   Up           23812090
  miRNA-124 (rno-miR-124-3p)                 Swimming                   Down         23812090

###### 

The KEGG pathways incorporated by downregulated miRNAs.

  KEGG pathway                                               −log⁡(*P* value)   Genes
  ---------------------------------------------------------- ------------------ -------------------------------------------------------------------------------------------------
  Fatty acid elongation                                      4.84               Hadha, Elovl6
  Arrhythmogenic right ventricular cardiomyopathy (ARVC)     2.94               Cacng4, Cacna2d1, Sgcd, Jup, Itgb8, Gja1
  Other types of O-glycan biosynthesis                       2.34               B3glct, Pomt2, Fut9, Colgalt2
  Thyroid hormone synthesis                                  2.04               Duox2, Tg
  Tyrosine metabolism                                        2.04               Maoa, Aldh1a3
  Mucin type O-Glycan biosynthesis                           1.76               Galnt16, Galnt7
  Other glycan degradation                                   1.66               Neu3
  Glycosphingolipid biosynthesis-lacto and neolacto series   1.66               B3galt2, Fut9
  Tryptophan metabolism                                      1.66               Afmid, Hadha, Tph2, Maoa, Ogdhl
  Gap junction                                               1.66               Tjp1, Egfr, Nras, Grm5, Gja1
  Proteoglycans in cancer                                    1.66               Wnt2, Cttn, Wnt4, Fgfr1, Egfr, Fn1, Nras, Erbb3, Rock2, Flna, Fzd3, Wnt2b, Pik3cd, Cav3, Ppp1cc
  Signaling pathways regulating pluripotency of stem cells   1.57               Fgfr3, Wnt2, Wnt4, Fgfr1, Nras, Nodal, Smad4, Fzd3, Wnt2b, Pik3cd, Acvr1c

###### 

The KEGG pathways incorporated by upregulated miRNAs.

  KEGG pathway                                               −log(*P* value)   Genes
  ---------------------------------------------------------- ----------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ECM-receptor interaction                                   55.86             Col2a1, Col3a1, Col6a3, Col1a1, Col4a4, Col5a2, Col5a3, Col4a1, Col4a3, Col11a1, Col4a2, Col5a1
  Fatty acid degradation                                     16.12             Hadha, Ehhadh, Acadm
  Fatty acid metabolism                                      9.93              Hadha, Ehhadh, Acadm
  Amoebiasis                                                 6.21              Col2a1, Col3a1, Col1a1, Prkx, Col4a4, Col5a2, Col5a3, Col4a1, Col4a3, Col11a1, Col4a2, Col5a1
  Fatty acid elongation                                      4.85              Hadha
  Protein digestion and absorption                           3.93              Col2a1, Col3a1, Col6a3, Col1a1, Col4a4, Col5a2, Col5a3, Col9a1, Col4a1, Col4a3, Col11a1, Atp1b4, Col4a2, Col5a1
  PI3K-Akt signaling pathway                                 2.81              Tsc1.Col2a1.Col3a1.Ddit4.Fgf.Col6a3.Lpar6.Fgf12.Eif4b.Col1a1.Irs1.Them4.Vegfa. Egfr.Ppp2ca.Ghr.Col4a.Tek.Col5a2.Osmr.Ppp2cb.Col5a.Ppp2r3c.Gng5.Col4a1. Col4a.Col11a1.Myb.Gnb3.Col4a.Col5a1.Kit
  Tyrosine metabolism                                        2.36              Maoa, ldh1a3
  Other types of O-glycan biosynthesis                       2.23              Pomt2, Fut9, Colgalt2
  Glycosphingolipid biosynthesis-lacto and neolacto series   1.81              B3galt2, Fut9
  Valine, leucine and isoleucine degradation                 1.81              Hadha, Ehhadh, Acadm
  Focal adhesion                                             1.41              Col2a1.Col3a1.Vav3.Col6a3.Col1a1.Vegfa.Crkl.Egfr.Col4a.Col5a2.Col5a3.Mylk. Col4a1.Col4a3.Col11a1.Col4a2.Col5a1.Ppp1ccsee interacti
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